Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Multicentre European Registry for Newly Diagnosed Patients With Myelodysplastic Syndromes (MDS), Including Acute Myeloid Leukaemia With 20-<30 Percent Marrow Blasts (Former RAEB-t), and Chronic Myelomonocytic Leukaemia (CMML)

NCT00600860 is registered in ClinicalTrials.gov with Radboud University Medical Center as lead sponsor.

NCT NCT00600860
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00600860 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Multicentre European Registry for Newly Diagnosed Patients With Myelodysplastic Syndromes (MDS), Including Acute Myeloid Leukaemia With 20-<30 Percent Marrow Blasts (Former RAEB-t), and Chronic Myelomonocytic Leukaemia (CMML)
Lead sponsor
Radboud University Medical Center
Phase
Observational
Overall status
Unknown status
Start date
April 30, 2008
Completion date
June 30, 2023
Enrollment
4,000 (estimated)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

myelodysplastic syndromes (mds)